Physician profile
Jan Mathisen
NPI 1275687766
$8,261.98
in general payments reported to CMS, 2019-2025
17 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $3,157 · 2021: $145 · 2022: $1,358 · 2023: $1,132 · 2024: $841 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,072.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $3,344.06 | 2020-2025 | Valtoco |
| Ucb, INC. | $2,376.01 | 2021-2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $1,079.73 | 2022-2025 | |
| Greenwich Biosciences, INC. | $483.70 | 2019-2020 | |
| Sk Life Science, INC. | $245.99 | 2021-2025 | Xcopri |
| Catalyst Pharmaceuticals, INC. | $127.29 | 2023-2025 | Fycompa |
| Sunovion Pharmaceuticals INC. | $125.21 | 2019 | |
| Biocodex, INC. | $103.03 | 2019 | |
| Acadia Pharmaceuticals INC | $89.17 | 2023-2025 | Daybue |
| Eisai INC. | $82.22 | 2022-2023 | |
| Zogenix INC. | $44.58 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $40.34 | 2023 | Aptiom |
| Livanova USA, INC. | $36.95 | 2020-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Pyros Pharmaceuticals, INC. | $29.62 | 2024 | Vigpoder |
| Immedica Pharma US, INC. | $22.31 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $16.63 | 2024 | Qelbree |
| Azurity Pharmaceuticals, INC. | $15.14 | 2025 | Zonisade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Mathisen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.